balaji jegannathan
2
Seguidores
Personal Information
Organização/Local de trabalho
Thanjavur Area, India India
Cargo
associate professor of medical oncology at regional cancer center kancheepuram
Marcadores
oncology geriatrics
oncology geriatrics
Ver mais
- Apresentações
- Documentos
- Infográficos
The Future of Antiangiogenic Therapies in Ovarian Cancer: A Series of Community and Academic Grand Rounds
Institute For Medical Education and Research (IMER)
•
Há 11 anos
Immunotherapy: an old dogma and evolving insight
Mohamed Abdulla
•
Há 7 anos
Challenges in managing adverse effects of immunotherapy treatment
SCGH ED CME
•
Há 6 anos
Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation
PVI, PeerView Institute for Medical Education
•
Há 3 anos
Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and Practical Guidance for Oncology Nurses
PVI, PeerView Institute for Medical Education
•
Há 4 anos
Patient perspective on immune oncology
LungCancerEU
•
Há 6 anos
Imugene Corporate Presentation
RedChip Companies, Inc.
•
Há 8 anos
IO Landscape Analysis - JPM18 - Aiman Shalabi
Arsalan Arif
•
Há 6 anos
Basic principles of cancer immunotherapy
Mohamed Abdulla
•
Há 5 anos
BioSci - IO Alliances
Mark Edwards
•
Há 5 anos
Cancer immunotherapy different modes of action - astra zeneca - jordan
Mohamed Abdulla
•
Há 6 anos
Taking Immunotherapy to the Next level
Company Spotlight
•
Há 7 anos
Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment
PVI, PeerView Institute for Medical Education
•
Há 1 ano
Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment
PVI, PeerView Institute for Medical Education
•
Há 1 ano
Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers
PVI, PeerView Institute for Medical Education
•
Há 2 anos
Making the Most of the New Era of Immuno-Oncology in TNBC: Essential Guidance for Surgeons on How to Maximize the Potential of Immunotherapies and Combinations in Advanced and Early-Stage Breast Cancer
PVI, PeerView Institute for Medical Education
•
Há 3 anos
On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
PVI, PeerView Institute for Medical Education
•
Há 4 anos
On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
PVI, PeerView Institute for Medical Education
•
Há 4 anos
Expanding Precision Medicine & Biomarker Strategy Options with RNAscope
William Baird
•
Há 6 anos
Optimizing Patient Outcomes in RCC Through Safe and Efficacious Use of Immuno-Oncology and Targeted Approaches: Teaming Up to Mitigate and Manage Adverse Events and Maximize Survival
PVI, PeerView Institute for Medical Education
•
Há 3 anos